Sources sought
Nitric Oxide 800PPm Gas
12313923
Department of the Army, W40M MRC0 West. In-Vitro Diagnostic Substance Manufacturing.
Response deadline
August 27, 2025 at 9:00 AM EDT
Closed 431 days ago. Posted August 19, 2025. Scheduled to archive September 11, 2025.
Get the next one like this from Department of the Army by email, the day it is posted.Find my opportunities
This one closed in 2025
13 like it are open now in in-vitro diagnostic substance manufacturing
- Blood Bank Reagents
Department of Veterans Affairs, 257-Network Contract Office 17
Sources soughtNAICS 325413Anywhere in the US36C25727Q0065Closes in 4 daysNov 5 - BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems
Defense Health Agency (Dha), Army Med Res Acq Activity
SolicitationSDVOSBNAICS 325413Anywhere in the USHT942627QE003Closes in 5 daysNov 6 - NOI - DNA Sequencing of Bone Marrow Failure Syndro
National Institutes of Health, National Institutes of Health Olao
Combined synopsis and solicitationNAICS 325413Anywhere in the US75N98027Q00027Closes tomorrowNov 2
Description
As published on SAM.gov.
The purpose of this sources sought notice is to conduct market research to determine if responsible sources exist by determining if this effort can be successfully competed and/or set-aside for Small Businesses. The proposed North American Industry Classification System (NAICS) Code is 325413 – In-Vitro Diagnostics Substance Manufacturing 1,250 employees. The Government will use this information to determine the best acquisition strategy for this procurement.
The Government is interested in all large and small businesses to include 8(a), Service-Disabled Veteran-Owned, HubZone, and Women-Owned small business concerns. The Medical Readiness Contracting Office-West (MRCO-W), JBSA, Fort Sam Houston, Texas, is seeking potential sources to establish a Nitric Oxide Gas Contract for the Department of Medicine at Brooke Army Medical Center (BAMC), JBSA – Fort Sam Houston, Texas.
This requirement is for the purchase of Inhaled Nitric Oxide (iNO) used in the various clinics to improve oxygenation in patients. Inomax is the brand name for inhaled nitric oxide (iNO). Nitric oxide (NO) is a naturally occurring gas produced in the body. It plays a crucial role in various physiological processes, most importantly in the regulation of blood vessel tone and blood flow.
This requirement shall consists of (a) the pharmaceutical drug INOmax® (nitric oxide) for inhalation (“INOmax”), (b) a delivery device meeting the criteria for the administration of INOmax set forth in the product label for INOmax (the “Delivery Device”), (c) various maintenance and calibration items, accessories, and disposables, (d) training, maintenance, pick-up and delivery, and other services, as described herein, including, without limitation, reimbursement support services.
Period of Performance: 1 January 2026 - 31 December 2030, One base year plus four (4) option years. This is not a solicitation. This information is for planning purposes only and is not to be construed as a commitment by the Government, implied or otherwise, to issue a solicitation or award a contract. Contractors responding to this sources sought notice are advised their response does not ensure participation in future solicitations or contract awards. The Government will not reimburse any company or individual for any expense associated with preparation or participation in this research. Interested parties should e-mail responses to wayne.shavers.civ@health.mil.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
August 19, 2025
Sources sought
Due August 27, 2025 at 9:00 AM EDT. SAM.gov, notice 75d81ce171764e6b9ce46809caaa6dd4
Points of contact
- Wayne Shaverswayne.shavers.civ@health.mil2104752192